A review of therapeutic agents for the management of pulmonary arterial hypertension

被引：10

作者：

Hahn, Stella S. ^{[1
]}

Makaryus, Mina ^{[1
]}

Talwar, Arunabh ^{[1
]}

Narasimhan, Mangala ^{[1
]}

Zaidi, Gulrukh ^{[1
]}

机构：

[1] Northwell Hlth, Div Pulm Crit Care & Sleep Med, 410 Lakeville Rd,Suite 107, New Hyde Pk, NY 11042 USA

来源：

THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE | 2017年 / 11卷 / 01期

关键词：

pulmonary arterial hypertension; prostanoid; endothelin receptor antagonist; phosphodiesterase inhibitor; soluble guanylate cyclase stimulator; ENDOTHELIN RECEPTOR ANTAGONIST; RANDOMIZED CONTROLLED-TRIAL; CONTINUOUS INTRAVENOUS EPOPROSTENOL; NITRIC-OXIDE SYNTHASE; 5 INHIBITOR THERAPY; DOUBLE-BLIND; INHALED ILOPROST; ORAL TREPROSTINIL; COMBINATION THERAPY; PROSTACYCLIN ANALOG;

D O I：

10.1177/1753465816665289

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Pulmonary arterial hypertension (PAH) is an uncommon, progressive and life threatening disease characterized by a proliferative vasculopathy of the small muscular pulmonary arterioles resulting in elevated pulmonary vascular resistance and eventually right ventricular failure. An increasing understanding of the pathobiology of PAH and its natural history has led to the development of numerous targeted therapies. Despite these advances there is significant progression of disease and the survival rate remains low. This article reviews the agents currently available for the medical management of PAH.

引用

页码：46 / 63

页数：18

共 50 条

[1] A review of the pharmacotherapeutic management of pulmonary arterial hypertension
Richard, L
VALUE IN HEALTH, 2003, 6 (03) : 308 - 308
[2] Review of the Diagnosis and Management of Pulmonary Arterial Hypertension
Woodard, Todd J.
Kim, Charles
Siao, Flora A.
US PHARMACIST, 2018, 43 (03) : HS10 - HS16
[3] Review of bosentan in the management of pulmonary arterial hypertension
Gabbay, Eli
Fraser, John
McNeil, Keith
VASCULAR HEALTH AND RISK MANAGEMENT, 2007, 3 (06) : 887 - 900
[4] A review of the pharmacotherapeutic management of pulmonary arterial hypertension
Richard, LJ
Howard, PA
Thorpe, T
VALUE IN HEALTH, 2002, 5 (06) : 492 - 493
[5] New Therapeutic Paradigms and Guidelines in the Management of Pulmonary Arterial Hypertension
Hill, Nicholas S.
Cawley, Michael J.
Heggen-Peay, Cherilyn L.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2016, 22 (03): : S3 - S19
[6] Therapeutic potential of natural flavonoids in pulmonary arterial hypertension: A review
Zhang, Jin-jing
Mao-mao
Shao, Min-min
Wang, Meng-chuan
PHYTOMEDICINE, 2024, 128
[7] Therapeutic targets in pulmonary arterial hypertension
Rhodes, Christopher J.
Davidson, Alexandra
Gibbs, J. Simon R.
Wharton, John
Wilkins, Martin R.
PHARMACOLOGY & THERAPEUTICS, 2009, 121 (01) : 69 - 88
[8] Pulmonary Arterial Hypertension and Therapeutic Interventions
Gabra, Nader B. Ishak
Mahmoud, Omar
Ishikawa, Oki
Shah, Varun
Altshul, Erica
Oron, Maly
Mina, Bushra
INTERNATIONAL JOURNAL OF ANGIOLOGY, 2019, 28 (02) : 80 - 92
[9] Management of Pulmonary Arterial Hypertension
Weatherald, Jason
Varughese, Rhea A.
Liu, Jonathan
Humbert, Marc
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 44 (06) : 746 - 761
[10] Management of Pulmonary Arterial Hypertension
Mayeux, Jennalyn D.
Pan, Irene Z.
Dechand, John
Jacobs, Joshua A.
Jones, Tara L.
McKellar, Stephen H.
Beck, Emily
Hatton, Nathan D.
Ryan, John J.
CURRENT CARDIOVASCULAR RISK REPORTS, 2021, 15 (01)

← 1 2 3 4 5 →